$2.71
+0.03 (+1.12%)
Open$2.71
Previous Close$2.68
Day High$2.72
Day Low$2.64
52W High$3.19
52W Low$1.60
Volume—
Avg Volume800.8K
Market Cap217.95M
P/E Ratio11.50
EPS$0.23
SectorBiotechnology
Analyst Ratings
Strong Buy
5 analysts
Price Target
+1,051.7% upside
Current
$2.71
$2.71
Target
$31.21
$31.21
$17.92
$31.21 avg
$31.70
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 54.00M | 52.20M | 361.03M |
| Net Income | -6,763,573 | -5,884,210 | 15.50M |
| Profit Margin | -12.5% | -11.9% | 4.3% |
| EBITDA | -4,133,741 | -3,796,088 | 29.24M |
| Free Cash Flow | — | — | 6.36M |
| Rev Growth | +3.5% | +3.5% | +17.6% |
| Debt/Equity | — | — | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $262.82 | +1.11% | 72.8 | 459.33B |
| AMGN | Amgen Inc | $403.04 | -1.04% | 25.1 | 219.33B |
| GILD | Gilead Sciences Inc | $144.74 | -1.87% | — | 179.15B |
| VRTX | Vertex Pharmaceuticals Inc | $504.73 | -0.40% | 30.1 | 132.51B |
| REGN | Regeneron Pharmaceuticals | $735.20 | +0.05% | 17.4 | 75.36B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.72 | -4.96% | 36.9 | 29.82B |